Texas A&M New Ventures Competition

Happy to report that our company has been selected by the Medical Device Innovation Consortium (MDIC) to be a part of their Advanced Manufacturing Clearing House program. In this program, working with MDIC and with guidance from the FDA, we will provide more detail to the medical device industry about AL's proprietary real-time operating system running on our devices to enable the building of digital twins of users joints, and what quantifiable improvements this approach creates for patients, providers, payors, and manufacturers. Overall goal is to show why this development can enable a new generation of medical devices offering improved task/activity-specific therapy and higher-resolution patient feedback without negatively impacting device cost, security risk, or quality of care. The work to be done in this project coincides nicely with existing goals for earning regulatory clearance and market validation for KneeStim while also opening up new possibilities for our RTOS' use in all kinds of medical devices. We've long talked about applying our base technology to other conditions and in other verticals - this is a definite step toward that future. We sincerely appreciate the faith shown in us by MDIC, particularly Steven Zera who helped shepherd us through this process, and look forward to sharing the outcomes of our work early next year. https://lnkd.in/dsabzW6P

Our healthcare team’s north star is investing in companies that realize better patient outcomes at lower costs. We’re proud to continue that momentum with our investment in VenoStent, Inc.’s Series A. VenoStent is seeking to improve the lives of more than 500,000 U.S. patients who receive life-saving dialysis to treat end-stage renal disease (ESRD) or kidney failure each year. The preferred access method (and current standard of care) for dialysis is creating an arteriovenous fistula (AVF) – a surgical connection between an artery and vein. But AVFs are rife with medical challenges, and a significant proportion of patients ultimately can’t use them for dialysis. In fact, only 40 percent of AVFs remain operational within one year after their creation. VenoStent, Inc. aims to dramatically improve outcomes for AVF patients with its bioabsorbable perivascular wrap, SelfWrap. SelfWrap’s early human studies have demonstrated the potential to significantly improve the AVF process and allow AVFs to remain functional longer. Once SelfWrap receives FDA approval, it could increase access to life-saving dialysis for ESRD patients. In short, we’re excited about VenoStent because:? ? They’re addressing a serious unmet need in a large patient population that has no other options ? The SelfWrap procedure is safe, fast, and easy to perform. Its first-in-human trial demonstrated compelling, first-of-a-kind results ? Their top-tier management team, board of directors, and team of advisors has extensive experience in medical device development and approval Read more from our General Partner Zack Scott and Investor Ehi Akhirome: https://lnkd.in/gAmkJU7V